Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05240118

Outcome of Discharged HFmrEF Patients — OUDI-HF  

Heart Failure With Mid Range Ejection Fraction Clinical Trial

Official title:
Risk Factors of Short-term and Long-term OUtcome in DIscharged Patients With Heart Failure With Mildly Reduced Ejection Fraction

Clinical Trial Summary

This study aimed to define the independent risk factors related cardiac events (cardiac death or heart failure-related hospitalization) among heart failure with mildly reduced ejection fraction (HFmrEF) patients who discharged from the Xiangtan Central Hospital. Through the long-term follow-up the cardiovascular outcome of patients being discharged from the hospital, the risk factors related to cardiovascular outcome (cardiac death or heart failure-related hospitalization) will be explored to provide clinical evidence to intervene the discharged HFmrEF patients aiming to improve patients outcome in the future clinical practice.

Clinical Trial Description

This study aimed to define the independent risk factors related cardiac events (cardiac death or heart failure-related hospitalization) among heart failure with mildly reduced ejection fraction (HFmrEF) patients who hospitalized in Xiangtan Central Hospital from January 1, 2015 to August 31, 2020. The patients would be clinically followed-up until August 31, 2021 per clinical visit or telephone call, the risk factors related to cardiovascular outcome (cardiac death or heart failure-related hospitalization) will be explored to provide clinical evidence to intervene the discharged HFmrEF patients aiming to improve patients outcome in the future clinical practice. The clinical features of hospitalized heart failure with mildly reduced ejection fraction (HFmrEF, EF 41-49%) will be analyzed by retrospectively by reviewing patients medical records, laboratory and clinical imaging examination results during initial hospitalization, clinical outcome of enrolled patients will be obtained through clinical visit and telephone call. The primary endpoint is the composite cardiac events (cardiac death or heart failure related rehospitalization). The secondary endpoint is the all-cause death. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05240118
Study type Observational
Source Xiangtan Central Hospital
Contact
Status Completed
Phase
Start date January 1, 2015
Completion date August 31, 2021
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05204238 - Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Enrolling by invitation NCT05600387 - Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction Phase 4
Terminated NCT04600921 - Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study Phase 3
Recruiting NCT05795400 - Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy N/A
Recruiting NCT05064709 - Assessment of CCM in HF With Higher Ejection Fraction N/A
Withdrawn NCT04632160 - Extended IASD Investigation: REDUCE LAP-HF IV N/A
Recruiting NCT05824923 - A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure Phase 3
Recruiting NCT03480633 - Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
Active, not recruiting NCT04862273 - Native T1 CMR Imaging for Diagnosis of Cardiac Amyloidosis